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ABSTRACT
Background. Inguinal lymph node metastases (ILNM)
from rectal adenocarcinoma are rare and staged as systemic
disease. This study aimed to provide insight into the
treatment and prognosis of ILNM from rectal
adenocarcinoma.
Methods. All patients with a diagnosis of synchronous or
metachronous ILNM from rectal adenocarcinoma between
January 2005 and March 2017 were retrospectively
reviewed.
Results. The study identified 27 patients with ILNM (15
with synchronous and 12 with metachronous disease).
After discussion by a multidisciplinary tumor board, 19
patients were treated with curative intent, 17 of whom
underwent inguinal lymph node dissection. Of the 17
patients, 12 had locally advanced rectal cancer (LARC)
with isolated ILNM, 3 had LARC and metastases else-
where, and 2 had locally recurrent rectal cancer (LRRC).
The median overall survival (OS) for all the patients treated
with curative intent was 27 months [95% confidence
interval (CI) 11.6–42.4 months], with a 5-year OS rate of
34%. The median OS for the patients with LARC and
isolated ILNM (n = 12) was 74 months (95% CI
18.0–130.0 months), with a 5-year OS rate of 52%. All the
patients with metastases elsewhere (n = 3) or LRRC
(n = 2) experienced recurrent systemic disease. Eight
patients were treated with palliative intent. The median OS
for this group was 13 months (95% CI 1.9–24.1 months),
with a 3-year OS rate of 0%.
Conclusion. Clinicians should not consider ILNM as an
incurable systemic disease. Patients with primary rectal
cancer and solitary ILNM who were eligible for curative
surgical treatment had a 5-year survival rate of 52%. The
prognosis for patients with additional systemic metastases
or LRRC is worse, and the benefit of surgery is unclear.
Locally advanced rectal cancer is associated with pelvic
lymph node metastases inside and sometimes outside the
mesorectum. Besides these locoregional lymph node
metastases, inguinal lymph node metastases (ILNM) may
occur, particularly in lower rectal cancer, due to the lym-
phatic drainage by inguinal lymph nodes.1 These ILNMs
are relatively rare, and the number of patients described in
the literature is low.2–7
The American Joint Committee on Cancer (AJCC)
Cancer Staging Manual considers ILNM from rectal cancer
as a systemic disease.8 Whether ILNM should be treated
with palliative or curative intent is unclear.9–11 Obviously,
patients with ILNM have a worse prognosis than patients
without ILNM, but even patients with lung or liver
metastases are not always restrained from curative treat-
ment.12 The evidence in the literature whether patients with
ILNM from rectal adenocarcinoma can possibly be cured is
scarce, and few studies have described treatment for ILNM
of rectal cancer.2,4–6
At our hospital, ILNM has been treated by inguinal
lymph node dissection (ILND), with and without neoad-
juvant chemotherapy, in case there were no other
metastases or when limited metastases were present
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elsewhere. This report presents the results for patients
treated with both curative and palliative intent for ILNM
from rectal cancer.
METHODS
All consecutive patients with ILNM from rectal ade-
nocarcinoma treated at the Erasmus MC Cancer Institute, a
tertiary referral center in the Netherlands, between January
2005 and March 2017, were retrospectively identified by a
search in the local pathology and rectal cancer database.
All patients with synchronous or metachronous ILNM were
included in the study. Patients with deep/iliac groin nodes
were not included.
Patient characteristics, collected from medical records,
included tumor characteristics, treatment, surgical vari-
ables, short- and long-term outcomes, and postoperative
mortality and morbidity. All the patients were followed up
at our institution, and the last update of follow-up evalu-
ation was 24 April 2018. Approval for this study was
granted by the local medical ethics committee (Registration
No. MEC-2017-448).
Synchronous ILNMs were defined as all ILNMs diag-
nosed before surgery for the primary rectal tumor.
Metachronous ILNMs were defined as all ILNMs diag-
nosed after surgery. All the patients with suspicious ILNMs
during physical examination or on imaging [computed
tomography (CT) of the abdomen or magnetic resonance
imaging (MRI) of the pelvis] underwent lymph node
biopsy.
All the patients were screened for disseminated disease
by CT of the thorax and abdomen. All the patients were
discussed by a multidisciplinary tumor board before treat-
ment and were assessed for eligibility to receive treatment
with curative or palliative intent.
Neoadjuvant (chemo)radiotherapy usually comprised a
cumulative dose of 50 Gy for primary rectal cancer and a
cumulative dose of 30 Gy for LRRC in fractions of
1.8–2.0 Gy, both with concomitant oral chemotherapy
(capecitabine 825–1000 mg/m2 for 5–7 days a week). The
target volume (95% of the radiation dose) mainly was the
rectum, but inguinal nodes often received a substantial
percentage (* 30–50%) of the radiation dose. Neoadju-
vant induction chemotherapy for ILNM was incidentally
given.
For the patients with synchronous ILNM who underwent
surgical treatment, an inguinal lymph node dissection
(ILND) was performed either simultaneously with surgery
for the rectal tumor or upfront before the start of neoad-
juvant treatment for the rectal tumor. In case of
metachronous metastases, an ILND was performed, in
some cases simultaneously with surgical removal of a local
recurrence. Notably, only superficial groin dissections were
performed.
Statistical analysis
Data are reported as median [interquartile range (IQR)
or 95% confidence interval] or mean ± standard deviation
as appropriate. Categorical data are reported as count (%).
The Kaplan–Meier method was used for survival analysis,
and a log rank test was performed for comparison. The
median follow-up period was calculated with the reversed
Kaplan–Meier method. Overall survival was calculated
from the day ILNM was diagnosed until death or the date
of the last follow-up visit. Statistical analysis was per-
formed using IBM SPSS Statistics version 24.0.0 for
Windows (IBM Corp, Armonk, New York, USA).
RESULTS
A flowchart of study patients is shown in Fig. 1. Patient
and primary tumor characteristics are listed in Table 1.
The characteristics of ILNM and follow-up evaluation are
shown in Table 2. The study identified 27 patients with
ILNM from rectal adenocarcinoma. The majority of the
ILNMs were from low rectal cancer (82%). The median
age at diagnosis of ILNM was 63 years (IQR 44–69 years).
The median interval between diagnosis of the primary
tumor and diagnosis of ILNM was 6 months (IQR
1–30 months). All the patients were discussed by a multi-
disciplinary tumor board, after which 19 patients were
treated with curative intent and 8 patients with palliative
intent.
Curative intent
For 10 of the 19 patients treated with curative intent,
neoadjuvant chemotherapy for ILNM was administered,
and all the patients received (chemo)radiotherapy for the
rectal tumor. For two patients, the target volume included
the ILNM. In all the remaining patients, the inguinal nodes
received a lower percentage (30–50%) of the total radiation
dose.
Two patients with primary rectal cancer had progression
of disease during neoadjuvant chemotherapy and were then
treated palliatively, as depicted in Fig. 1. Subsequently,
ILND was performed for 17 patients. Of these 17
patients,12 had primary locally advanced rectal cancer and
solitary ILNM, 3 had metastases elsewhere (liver, n = 2;
peritoneal, n = 1), and 2 patients had locally recurrent
rectal cancer.
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Palliative intent
Eight patients were treated with palliative intent for
disseminated disease or unresectable LRRC using
chemotherapy, radiotherapy, or terminal care, as displayed
in Fig. 1. Five of these patients had received neoadjuvant
radiotherapy for the rectal tumor, and the ILNMs were
outside the target volume but still received a lower per-
centage (30–50%) of the total radiation dose. Two patients
had received palliative radiotherapy with ILNM receiving
the target volume, a dose of 32 and 45 Gy, respectively.
Mortality and morbidity
Curative intent None of the patients died within 30 days
of surgery, and 6 (35%) of the 17 patients experienced
postoperative complications. Four patients experienced
inguinal seroma despite the standard use of postoperative
suction drainage, which required percutaneous drainage in
all cases. Two patients used antibiotics to treat superficial
wound infections. Two patients experienced lymphedema
during the follow-up period and required elastic
compression garments.
Of all the patients with inguinal complications, one
patient had received neoadjuvant radiotherapy specifically
on the inguinal nodes. In all the remaining patients, the
inguinal nodes were outside the target area but still partly
inside the radiotherapy field.
Palliative intent Half of the patients who received
palliative treatment had ILNM-related morbidity. Four
patients experienced severe pain requiring intravenous pain
medication, and three of these patients also had
lymphedema. One patient experienced lymphedema
without complaints. Four patients with lymphedema had
received radiotherapy for the rectal tumor, with inguinal
nodes partly in the radiation field. Two of these patients
also had received a high-dose palliative radiotherapy
ILNM from rectal adenocarcinoma N=27
(synchronous N=15 and metachronous N=12)
Curative intent (N=19) Palliative intent (N=8)
ILNM with metastases
elsewhere (N=3) or LRRC (N=2)
Solitary ILNM and primary
rectal cancer (N=14)
ILNM with other
unresectable distant
metastases* (N=5)
ILNM and unresectable
LRRC* (N=3)
Neoadjuvant CTx ILNM (N=2)
No neoadjuvant CTx ILNM (N=3)
Neoadjuvant CTx ILNM (N=8)
No neoadjuvant CTx ILNM (N=6)
CTx (N=4)
Terminal care (N=1)
RTx (N=2)
CTx (N=1)
Upfront ILND (N=2)
Simultaneous ILNd (N=1)
Metachronous ILND (N=2)
Upfront ILND (N=5)
Simultaneous ILNd (N=3)
Metachronous ILND (N=4)
Progressive disease and no
dissection (N=2)
CTx (N=1)
Terminal care (N=1)†
FIG. 1 Flowchart included patients. ILNM inguinal lymph node
metastases, ILND inguinal lymph node dissection, LRRC locally
recurrent rectal cancer, CTx chemotherapy, RTx radiotherapy,
Upfront, upfront dissection before resection of rectal tumour;
Simultaneous, simultaneous resection with rectal tumour,
Metachronous, resection during follow up rectal tumour.*Reason
palliative treatment; Died of respiratory failure before treatment
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TABLE 1 Patient and primary
tumor characteristics
Total Curative intent Palliative intent
n = 27
n (%)
n = 19
n (%)
n = 8
n (%)
Gender
Male 12 (44) 7 (73) 3 (38)
Female 15 (56) 12 (63) 5 (63)
Age at ILNM diagnosis
Median (IQR) 63 (44–69) 60 (40–69) 64 (57–67)
ASA
ASA 1–2 25 (93) 18 (95) 7 (78)
ASA[ 2 2 (7) 1 (5) 1 (13)
Rectal tumor at ILNM diagnosis
Primary 21 (78) 17 (90) 4 (50)
LRRC 6 (22) 2 (11) 4 (50)
Distance from anal verge (cm)
Median (IQR) 2 (1–3) 1 (0–7) 2 (1–3)
Location of rectal tumor
Low rectal (\ 5 cm) 22 (82) 14 (74) 8 (100)
Mid rectal (5–10 cm) 3 (11) 3 (16) 0 (0)
High rectal ([ 10 cm) 2 (7) 2 (11) 0 (0)
Neoadjuvant therapy for rectal tumor
CTxRTx 18 (67) 14 (74) 4 (50)
RTx 4 (15) 3 (11) 1 (13)
CTx 0 (0.0) 0 (0) 0 (0)
No neoadjuvant therapy 5 (19) 2 (11) 3 (38)
Surgical procedure for primary tumor
No resectiona 2 (5) 2 (11) 0 (0)
LAR 7 (26) 4 (21) 3 (38)
APR 9 (33) 5 (26) 4 (50)
APR with HIPEC 1 (4) 1 (5) 0 (0)
Posterior pelvic exenteration 4 (15) 3 (16) 1 (13)
Total pelvic exenteration 4 (15) 4 (21) 0 (0)
Tumor stage of primary tumor
No resection 2 (8) 2 (11) 0 (0)
T2 3 (11) 2 (11) 1 (13)
T3 11 (41) 7 (37) 4 (50)
T4 11 (41) 8 (42) 3 (38)
Nodal stage of primary tumor
No resection 2 (7) 2 (11) 0 (0)
N0 10 (37) 5 (26) 5 (63)
N1 8 (30) 6 (32) 2 (25)
N2 7 (26) 6 (32) 1 (13)
Numbers do not add up due to rounding
ILNM inguinal lymph node metastases, IQR interquartile range, ASA American Society of Anesthesiology,
LRRC locally recurrent rectal cancer, CTxRTx chemoradiotherapy, RTx radiotherapy, CTx chemotherapy,
LAR low anterior resection, APR abdominoperineal resection, HIPEC hyperthermic intraperitoneal
chemotherapy
aNo resection due to progressive disease
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TABLE 2 Inguinal lymph
node metastases and
histopathologic characteristics
and follow-up evaluation
Total Curative intent Palliative intent
n = 27
n (%)
n = 19
n (%)
n = 8
n (%)
Time from Dx of rectal cancer until ILNM
Median months (IQR) 6 (1–30) 4 (0–4) 24 (4–56)
Onset of ILNM
Synchronous 15 (56) 13 (68) 2 (25)
Metachronous 12 (44) 6 (32) 6 (75)
Location of ILNM
Unilateral 19 (70) 14 (74) 5 (63)
Bilateral 8 (30) 5 (26) 3 (38)
Solitary ILNM
No 8 (30) 3 (16) 5 (63)
Yes 19 (70) 16 (84) 3 (38)
Distant metastases elsewhere
Liver 1 (4) 1 (5) 0 ()
Lung 1 (4) 0 () 1 (13)
Peritoneal 2 (7) 1 (5) 1 (13)
Iliac lymph nodes and paraaortic 1 (4) 0 (0) 1 (13)
Lung and spinal bone 1 (4) 0 (0) 0 ()
Liver and iliac lymph nodes 2 (7) 1 (5) 1 (13)
Lung and iliac lymph nodes 2 (7) 0 (0) 1 (13)
Neoadjuvant CTx for ILNM
No 17 (63) 9 (47) N/A
Yes 10 (27) 10 (53) N/A
ILND
No dissection 10 (37) 2 (11) 8 (100)
Upfront 7 (26) 7 (37) 0 (0)
Simultaneous with rectal tumor 4 (15) 4 (21) 0 (0)
Metachronous during FU of rectal cancer 6 (22) 6 (37) 0 (0)
Histopathology of inguinal lymph nodes specimena
Positive lymph nodes
No NA 4 (24) NA
Yes NA 13 (76) NA
Total no. of harvested nodes
Median (range) NA 12 (3–16) NA
Total no. of positive nodes
Median (range) NA 1 (0–11) NA
Follow-up after surgical treatment
Disease status at last follow-up
No evidence of disease NA 5 (29) NA
Distant metastases NA 7 (41) NA
Local recurrence of rectal cancer and NA 7 (41) NA
Distant metastases
Inguinal lymph node recurrenceb NA 2 (12) NA
Numbers do not add up due to rounding
Dx diagnosis, ILNM inguinal lymph node metastases, IQR interquartile range, CTx chemotherapy, ILND
inguinal lymph node dissection, FU follow-up, NA not applicable
a17 patients and 22 dissection specimens, due to five bilateral ILN
bNodal recurrence in dissected site
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specifically on the inguinal nodes, but already had
experienced lymphedema before palliative radiotherapy.
Histopathologic results after ILND
Histopathologic evaluation was performed for 22 dis-
section specimens from 17 patients. The median number of
lymph nodes found was 12 (range 3–26), and the median
number of positive lymph nodes was 1 (range 0–11).
In four patients treated with curative intent, no positive
lymph nodes were found. Three of these four patients had
received neoadjuvant chemotherapy and were considered
complete responders. In one patient without neoadjuvant
therapy, three negative nodes were recovered, but four
tumor deposits in the specimen were found, and this patient
experienced local and distant recurrence during the follow-
up period. In the remainng 13 patients, positive lymph
nodes were found. Of these 13 patients, 5 had received
neoadjuvant chemotherapy for ILNM.
Follow-up evaluation, recurrence, and survival
The median follow-up period for the survivors in the
total cohort of 27 patients was 79 months (95% CI
46.9–111.1 months), during which 20 patients died. The
median overall survival for the total cohort was 19 months
(95% CI 5.8–32.2 months). There was no significant dif-
ference in survival between synchronous or metachronous
ILNM (p = 0.86) and bilateral or unilateral ILNM
(p = 0.05).
Curative intent Of 19 patients treated with curative
intent, 2 had progressive disease under neoadjuvant therapy
and experienced distant metastases, whereas the primary
rectal tumor and the ILNM remained in situ. At the last
follow-up visit, 5 of the 17 patients who underwent ILND
had no evidence of disease. Of these 17 patients, 2
experienced a local ILNM recurrence, accompanied by
local recurrence of the rectal tumor and systemic
metastases. Another five patients experienced local
recurrence of the rectal tumor with distant metastases,
and five patients experienced distant metastases alone.
At the last follow-up visit, seven patients were alive, and
all these patients had undergone ILND. Three patients were
alive with local rectal tumor recurrence and distant
metastases, including one patient with ILNM recurrence.
Four patients were alive with no evidence of disease, and
one patient had died with no evidence of disease.
Survival curves are shown in Fig. 2. The median overall
survival for all 19 patients treated with curative intent after
diagnosis was 27 months (95% CI 11.6–42.4 months). The
1- and 5-year estimated overall survival rates were
respectively 79% and 34%.
For 12 patients with solitary ILNM from primary rectal
cancer without systemic metastases who underwent cura-
tive ILND, the median overall survival period was
74 months (95% CI 18.0–130.0 months) with 1- and 5-year
estimated overall survival rates of 83% and 52%,
respectively.
Three patients underwent ILND with resection of the
primary rectal tumor and resection of metastases elsewhere
(liver, n = 2; peritoneal, n = 1). Two of these patients died
of systemic disease at 13 and 26 months of follow-up
evaluation, respectively, and one patient, who underwent
ILND and surgery for primary rectal cancer with liver
metastases only, at this writing is still alive after 14 months
of follow-up evaluation with locally recurrent rectal cancer
and recurrent liver metastases. The two patients who
underwent ILND with simultaneous resection of locally
recurrent rectal cancer died of systemic disease with
respectively 12 and 13 months of follow-up evaluation.
Palliative treatment intent At the last follow-up visit, all
eight patients treated with palliative intent had died of the
disease. The median overall survival was 13 months (95%
CI 1.9–24.1 months), with 1- and 3-year estimated overall
survival rates of 63% and 0%, respectively.
DISCUSSION
In this study, a 5-year survival rate of 52% was achieved
after surgical treatment of patients with primary rectal
cancer. An isolated ILNM prognosis for patients with
additional systemic metastases is worse, and the benefit of
surgery is unclear. Patients treated with curative surgery
mostly experienced lymphedema, and palliatively treated
patients mostly had severe pain.
In 1990, Graham and Hohn7 were among the first to
describe management of ILNM. Their study identified 40
patients with ILNM from rectal cancer divided into three
groups: (1) unresectable primary tumors, (2) recurrent
disease after abdominoperineal resection with palliative
treatment, and (3) solitary ILNM treated with ILND. None
of the patients survived 5 years, but the median survival
was highest in the solitary ILNM group (inguinal metas-
tases only), with two patients having no evidence of disease
at the last follow-up visit (one patient died of myocardial
infarction, and one patient was alive with 15 months of
follow-up evalution). These authors concluded that only in
case of solitary ILNM, the situation for eight patients in
their study, a resection may be warranted.
Tocchi et al.4 reported a mean, not median, survival of
14.8 months for 21 patients with ILNM from rectal cancer,
and none of the patients reached 5-year survival. Their
study included five patients with ILNM only and supported
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the suggestion that ILND can be beneficial, although not
curative, because a prolonged survival was achieved for
these patients. They concluded that ILNM is frequently
associated with distant metastases (in 16 of 21 patients of
their series), and in these cases, systemic therapy is the
treatment of choice.
Luna-Pe´rez et al.6 described a 5-year survival for 0% of
32 patients with ILNM from rectal adenocarcinoma, 27 of
whom also had systemic metastases. They concluded that
surgery for isolated ILNM may prolong survival, but that
ILNM should be considered as systemic disease and treated
palliatively as indicated.
More recent studies by Bardia et al.2 and Adachi et al.5
retrospectively reviewed small groups of patients with
ILNM and concluded that patients with isolated ILNM are
a different subset of patients. Bardia et al.2 studied six
patients with solitary ILNM, and the mean survival period
for these patients was 40 months. Adachi et al.5 studied 10
patients with ILNM, 8 of whom had solitary ILNM and
underwent ILND. They reported a 5-year overall survival
rate of 75% for these patients. Adachi et al.5 also reported a
better prognosis for patients with metachronous metastases,
but our study did not find any difference in survival
between metachronous and synchronous metastases. This
may be explained by the definitions Adachi et al.5 used for
synchronous (up to 1 year after diagnosis of the primary
rectal cancer) and metachronous metastases ([ 1 year after
diagnosis of primary rectal cancer) or by the small number
of patients in both studies.
The current study presents the largest group of patients
with ILNM caused by rectal cancer who were treated with
curative intent since the study by Luna-Pe´rez et al.6 in
1999. However, the majority of the patients in the latter
study had distant metastases as well and may not be con-
sidered candidates for curative treatment. The results of
previous studies presenting smaller groups of patients are
confirmed: ILNM caused by rectal cancer should not nec-
essarily be considered an incurable disease, especially in
case of primary rectal cancer and the absence of other
systemic metastases. In our study, a median OS of
74 months with 1- and 5-year estimated overall survival
rates of 83% and 52%, respectively, was reached for this
group.
In line with all other previously published studies, our
study showed a poor prognosis for the patients with ILNM
and distant metastases to other sites.2,4–7 These results
suggest that these patients should be treated with palliative
intent.
The current study included three patients who under-
went resection of ILNM combined with resection of
additional metastases. Only one patient, who underwent
ILND and liver metastases resection, at this writing is still
alive at 14 months follow-up evaluation, with systemic
recurrence. In addition, both patients with locally recurrent
rectal cancer who underwent resection of the rectal tumor
with ILND died within 13 months. Due to small numbers,
no conclusions can be drawn, and it is unclear whether
surgery was at all beneficial for these patients. Currently, in
the Netherlands, the ORCHESTRA trial is being performed
to assess the beneficial effects of added local treatment
with systemic treatment in case of systemic disease and
possibly will provide evidence in the future.13
The mortality and morbidity associated with ILND have
been described for ILNM caused by melanoma and anal
cancer, but few studies have described morbidity after
ILND for rectal cancer.14–16 The mortality is low, but the
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morbidity associated with this procedure is high. Short-
term wound complications such as dehiscence, infection,
and seroma are reported to reach 60%, and lymphedema
can occur.14–16
In our study, 6 (35%) of 17 patients experienced post-
operative complications. All the patients with inguinal
complications had received (partial) prior irradiation on
inguinal nodes. The numbers were small in the current
study, but the negative impact of radiation therapy is well
known. Radiation therapy impairs wound healing and can
increase the incidence of lymphedema.17 Recent series
indicate that routine inguinal lymph node radiation is not
necessary.17,18 The optimal balance between inguinal
radiotherapy and the extent of surgery is unclear, but the
morbidity of the combined procedure should not be
underestimated.
In the current study, only ILND (i.e., superficial groin
dissections) were performed and no deep groin dissec-
tion. In 12 of the 17 patients who underwent ILND, distant
metastases occurred outside the pelvic region, including
four patients with simultaneous iliac node recurrence. This
could imply that a formal deep groin dissection in all these
patients for a superficial ILNM would have been
overtreatment with considerable morbidity.
Our study was limited by its small numbers, referral bias
from other centers, and its retrospective nature. Inguinal
lymph node metastases from rectal adenocarcinoma are
relatively rare, and most previous studies contain small and
heterogeneous groups of patients collected before the era of
total mesorectal excision (TME) surgery and before
neoadjuvant therapy was widely accepted. Although the
current study presents a small cohort, it provides proof that
solitary ILNM from rectal adenocarcinoma does not equal
incurable disease. This is supported by previous reports.
CONCLUSION
Surgical treatment of ILNM from rectal adenocarcinoma
may result in prolonged survival and possibly a cure.
Inguinal lymph node metastases should not be considered
as an incurable disease, especially in patients with primary
rectal cancer and solitary ILNM. The prognosis for patients
with ILNM and distant metastases elsewhere or recurrent
rectal cancer is worse, and the value of surgery is unclear.
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